NEW YORK – The UK's National Institute for Health and Care Excellence published a final draft guidance on Tuesday recommending venetoclax (AbbVie's Venclyxto) plus obinutuzumab (Roche's Gazyva) without chemotherapy for untreated chronic lymphocytic leukemia (CLL) patients with certain genetic mutations.